Amgen, Allergan’s Herceptin biosimilar filed in the US

1st August 2017 Uncategorised 0

US biotech giant Amgen and Dublin, Ireland-based Allergan have now filed ABP 980 – a biosimilar version of Roche’s blockbuster biologic trastuzumab – with the US Food and Drug Administration.

More: Amgen, Allergan’s Herceptin biosimilar filed in the US
Source: News